ATNIVS biomarker heterogeneity in real-world patients receiving lecanemab - 12/04/26
, Ryoko Ihara a, b, Gen Yoshii a, Ryosuke Shimasaki a, Keiko Hatano a, Taro Bannai a, Fumio Suzuki c, Kenji Ishibashi d, Ko Furuta e, Katsuya Satoh f, Aya Midori Tokumaru c, Kenji Ishii b, d, Atsushi Iwata a, b
Bienvenue sur EM-consulte, la référence des professionnels de santé.
Article gratuit.
Connectez-vous pour en bénéficier!
Abstract |
Background |
While amyloid-β (Aβ) biomarker positivity is sufficient before initiating anti-Aβ antibody therapy, recent revised criteria also highlight the importance of other biomarkers (ATNIVS) to understand heterogeneity in AD.
Design, Setting, and Participants |
We reviewed patients who attended our specialty clinic between December 2023 and October 2024. Some participated in tau PET study ( 18 F-MK6240). MRI was assessed using Fazekas score. Remaining samples were analyzed for plasma neurofilament light chain (NfL), glial fibrillary acidic protein (GFAP), and CSF α-synuclein seed amplification assay (SAA).
Results |
During the period, 200 attended and 147 proceeded to screening. Lecanemab was started in 93 of 108 A+ patients; mean age 74.2 years, 73.1% female. While all tested started on lecanemab were positive on amyloid PET, 21% had only regional positivity with lower Aβ burden (centiloid 31.3 ± 17.5 vs 67.6 ± 20.2) and higher age (79.2 ± 5.1 vs 73.3 ± 8.9). While all tested had CSF Aβ42/40 values below the single cut-off 0.067 in Japan, three (8.6%) had values close to the cutoff (0.059–0.067), all of whom were male. Other biomarkers also widely varied from normal to fully abnormal; CSF pTau181 (40.5–168 pg/mL, cut-off 56.5), tau PET-based Braak stage (0–VI), NfL (10.0–103.3 pg/mL), GFAP (121.9–652.5 pg/mL), Fazekas score (0–3), and positive α-synuclein SAA (25–33%). Some associations were indicated including higher Fazekas scores in amyloid PET regional-positive group and higher plasma NfL in CSF Aβ42/40 0.059–0.067 group.
Conclusions |
We identified substantial heterogeneity in ATNIVS biomarker profiles among patients receiving lecanemab in a real-world setting.
Le texte complet de cet article est disponible en PDF.Keywords : Alzheimer’s disease, Lecanemab, ATNIVS biomarkers, Amyloid-β, Tau pathology, Real-world study, Biomarker heterogeneity, Amyloid PET, Cerebrospinal fluid biomarkers, α-synuclein co-pathology
Plan
Vol 13 - N° 6
Article 100567- juin 2026 Retour au numéro
Article précédent
- Knowledge and perception of dementia risk and protective factors: a systematic review and meta-analysis
- Muhammed L. Sambou, Jolanda H.M. Dobbe, Elaine A.C. Albers, Kay Deckers, Lidia R. Arends, M. Arfan Ikram, Ellen M.A. Smets, Wichor M. Bramer, Jeremy A. Labrecque, Leonie N.C. Visser, Frank J. Wolters
- Comparative effects of some pharmacological and non-pharmacological interventions on cognitive function in Alzheimer’s disease: A Bayesian network meta-analysis
- Yuning Zhao, Guangxin Luo, Can Huang, Zhenyang Chen, Yu Wei, Qiaosen Chen, Fang Wang, Yong Gan, Xiaoxv Yin
Bienvenue sur EM-consulte, la référence des professionnels de santé.